These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22729556)

  • 21. CD8
    Shore ND; Morrow MP; McMullan T; Kraynyak KA; Sylvester A; Bhatt K; Cheung J; Boyer JD; Liu L; Sacchetta B; Rosencranz S; Heath EI; Nordquist L; Cheng HH; Tagawa ST; Appleman LJ; Tutrone R; Garcia JA; Whang YE; Kelly WK; Weiner DB; Bagarazzi ML; Skolnik JM
    Mol Ther; 2020 May; 28(5):1238-1250. PubMed ID: 32208168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
    Knight D; Peterson AC; Rini BI; Harlin H; Gajewski TF; Stadler WM
    Prostate; 2009 Feb; 69(2):142-8. PubMed ID: 18942640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunology; 2006 Mar; 117(3):419-30. PubMed ID: 16476062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
    Johnson LE; Frye TP; Chinnasamy N; Chinnasamy D; McNeel DG
    Cancer Immunol Immunother; 2007 Jun; 56(6):885-95. PubMed ID: 17102977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
    Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
    Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.
    Feyerabend S; Stevanovic S; Gouttefangeas C; Wernet D; Hennenlotter J; Bedke J; Dietz K; Pascolo S; Kuczyk M; Rammensee HG; Stenzl A
    Prostate; 2009 Jun; 69(9):917-27. PubMed ID: 19267352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation.
    Roos AK; Moreno S; Leder C; Pavlenko M; King A; Pisa P
    Mol Ther; 2006 Feb; 13(2):320-7. PubMed ID: 16185933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
    Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
    J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
    Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
    Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.
    Kang TH; Chung JY; Monie A; Pai SI; Hung CF; Wu TC
    Gene Ther; 2010 Apr; 17(4):531-40. PubMed ID: 19940864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
    Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
    Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1.
    Campos-Perez J; Rice J; Escors D; Collins M; Paterson A; Savelyeva N; Stevenson FK
    Int J Cancer; 2013 Sep; 133(6):1400-7. PubMed ID: 23494538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
    Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
    J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA vaccines: an active immunization strategy for prostate cancer.
    Wolchok JD; Gregor PD; Nordquist LT; Slovin SF; Scher HI
    Semin Oncol; 2003 Oct; 30(5):659-66. PubMed ID: 14571413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).
    Perambakam S; Xie H; Edassery S; Peace DJ
    Clin Dev Immunol; 2010; 2010():473453. PubMed ID: 21253471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
    Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
    Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial.
    Brill TH; Kübler HR; Pohla H; Buchner A; Fend F; Schuster T; van Randenborgh H; Paul R; Kummer T; Plank C; Eisele B; Breul J; Hartung R; Schendel DJ; Gansbacher B
    Hum Gene Ther; 2009 Dec; 20(12):1641-51. PubMed ID: 19671000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
    Giannopoulos K; Dmoszynska A; Kowal M; Rolinski J; Gostick E; Price DA; Greiner J; Rojewski M; Stilgenbauer S; Döhner H; Schmitt M
    Leukemia; 2010 Apr; 24(4):798-805. PubMed ID: 20220777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.